SALT LAKE CITY, Oct. 29, 2008 (GLOBE NEWSWIRE) -- BSD Medical Corporation (Nasdaq:BSDM) today announced that an article titled "Hyperthermia induced targeting of thermosensitive gene carriers to tumors" was published in a recent edition of Human Gene Therapy, the official journal of the European Society of Gene and Cell Therapy (Pubmed 18729717). Researchers from Ludwig-Maximilians University, Pharmaceutical Biology-Biotechnology, Department of Pharmacy, Munich, Germany "developed a gene delivery system based on thermosensitive block copolymers (TSC) with a phase transition temperature of 42 degrees C." The researchers reported that a preclinical study demonstrated that the addition of hyperthermia therapy can improve the efficiency of virus mediated transgene expression.
